Chlordiazepoxide

證據等級: L5

預測適應症: 10 個

Chlordiazepoxide: From Anxiety & Alcohol Withdrawal to Insomnia

One-Sentence Summary

Chlordiazepoxide (Librium) is the first benzodiazepine ever developed, historically used for anxiety disorders and alcohol withdrawal management. The TxGNN model predicts it may be effective for Insomnia, with no directly relevant clinical trials and 6 publications currently identified in support of this direction. Evidence is predominantly observational and review-level, placing this at Evidence Level L3 — with a Hold recommendation given the drug’s unfavorable pharmacokinetic profile and modern clinical guidelines that explicitly discourage long-acting benzodiazepines for insomnia.

Quick Overview

Item	Content
Original Indication	Anxiety disorders; alcohol withdrawal (historical class use — no regulatory records found in database)
Predicted New Indication	Insomnia
TxGNN Prediction Score	99.998%
Evidence Level	L3
US Market Status	No records retrieved (0 NDAs in database)
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on well-established pharmacological knowledge, chlordiazepoxide — the prototypical benzodiazepine — acts as a positive allosteric modulator of the GABA-A receptor. It enhances the inhibitory effect of γ-aminobutyric acid (GABA), producing sedation, anxiolysis, muscle relaxation, and anticonvulsant activity. This GABA-A enhancement can shorten sleep onset latency and increase NREM sleep proportion, forming the mechanistic basis for the TxGNN insomnia prediction.

Anxiety and insomnia are neurobiologically intertwined. Chronic hyperarousal — a core feature of anxiety disorders — directly impairs both sleep initiation and sleep maintenance. Chlordiazepoxide’s broad CNS depressant effects naturally extend to sleep induction, and the benzodiazepine class as a whole was the dominant pharmacological treatment for insomnia for decades before Z-drugs (zolpidem, eszopiclone) and orexin receptor antagonists became available. Controlled studies confirm that benzodiazepines as a class produce short-term improvements in sleep latency and total sleep time (PMID 2883822). It is also noteworthy that TxGNN independently ranked “sleep disorder, initiating and maintaining sleep” (DIMS — the historical ICD classification for insomnia) at rank 6, with a largely overlapping evidence base including two direct RCTs involving chlordiazepoxide in sleep-related contexts, further corroborating the model’s signal.

However, the clinical case for chlordiazepoxide specifically in insomnia is substantially weakened by its pharmacokinetic profile. Its half-life of 5–30 hours — compounded by active metabolites (desmethylchlorodiazepoxide, demoxepam) with even longer half-lives — causes significant next-day residual sedation and drug accumulation with repeated nightly dosing. Current sleep medicine guidelines explicitly recommend against long-acting benzodiazepines as first-line insomnia therapy. The risk of falls, cognitive impairment, delirium, tolerance, and physical dependence is particularly high in elderly patients, who appear on the Beers Criteria as a protected population. These factors collectively explain the Hold recommendation despite a near-perfect TxGNN prediction score.

Clinical Trial Evidence

Currently no related clinical trials registered.

Note: One trial was retrieved (NCT01109030: Pioglitazone as adjunct for moderate-to-severe depression, Phase 2/3, n=50). This was assessed as a pipeline mismatch (Grade C relevance — different drug and unrelated indication) and is not counted as supporting evidence for chlordiazepoxide in insomnia.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
4628683	1972	Clinical Trial	Current Therapeutic Research	Clinical evaluation of chlordiazepoxide efficacy in anxious outpatients; demonstrates anxiolytic and sedative effects with indirect relevance to sleep-onset difficulty
2883822	1986	Review	Acta Psychiatrica Scandinavica (Suppl)	Pharmacodynamic review of benzodiazepine hypnotics in elderly; controlled studies show 2–3× increased sensitivity in older adults; elevated fall and cognitive impairment risk with long-acting agents
23330992	2013	Review	Expert Opinion on Drug Metabolism & Toxicology	Pharmacokinetic review of anxiolytic drugs; highlights implications of long half-lives and active metabolites for dosing and tolerability in anxiety/sleep disorders
6111745	1981	Review	The Medical Letter	Comparative guidance on benzodiazepine selection; discusses trade-offs between long-acting and short-acting agents for anxiolytic and sedative-hypnotic use
30680986	2019	Cross-sectional	Medicinski Glasnik	Prevalence of potentially inappropriate medications (PIMs) in elderly Iranians; chlordiazepoxide flagged per Beers Criteria 2012, underscoring ongoing safety concerns in routine clinical practice
14085195	1963	Case Series	Acta Psychiatrica Scandinavica	Early case series of a Librium metabolite (Ro 4-5360) in anxiety neuroses and psychosomatic syndromes; historical context only, no modern insomnia endpoints

Safety Considerations

Please refer to the package insert for safety information.

The following signals are identified from available literature and known pharmacology:

Elderly Population Risk: Chlordiazepoxide is listed on the American Geriatrics Society Beers Criteria as a potentially inappropriate medication (PIM) for older adults. Elderly patients show 2–3× increased pharmacodynamic sensitivity compared to younger adults, with significantly elevated risk of falls, hip fractures, cognitive impairment, and delirium (PMID 2883822; PMID 30680986).
Dependence and Withdrawal: Long-term benzodiazepine use carries substantial risk of physical dependence. Abrupt discontinuation may precipitate a clinically significant withdrawal syndrome, including rebound insomnia, anxiety, tremor, and seizures — paradoxically worsening the very condition being treated.
Next-Day Residual Effects: Due to the long half-life and active metabolites, repeated nightly dosing is expected to cause daytime sedation, psychomotor impairment, and anterograde memory impairment — particularly problematic in occupational and driving safety contexts.
Drug Interactions: No DDI data was retrieved from the database. Clinically, additive CNS depression is expected with opioids, alcohol, antipsychotics, antihistamines, and other sedative-hypnotics — a combination that substantially increases respiratory depression risk.

Conclusion and Next Steps

Decision: Hold

Rationale: Although chlordiazepoxide’s GABA-A mechanism provides a biologically plausible basis for insomnia management, its long half-life, accumulating active metabolites, unfavorable risk profile in elderly patients, and explicit deprioritization in modern insomnia clinical guidelines make it a poor repurposing candidate. No directly relevant RCTs exist, and the available literature is predominantly historical, observational, or review-level.

To proceed, the following is needed:

Verify US FDA regulatory status directly via the FDA Orange Book and DailyMed (current database shows 0 records, which likely reflects a data retrieval gap rather than true non-approval)
Retrieve and parse the full package insert to complete the safety profile (DG001: TFDA/FDA warnings and contraindications)
Obtain complete mechanism of action data from DrugBank API (DG002: MOA description)
Define a specific clinical niche where chlordiazepoxide’s profile might offer a genuine advantage — for example, short-term management of insomnia comorbid with acute anxiety in non-elderly adults, where anxiolytic and hypnotic effects can be leveraged together
If pursuing further, conduct a systematic comparison of safety outcomes between chlordiazepoxide and shorter-acting benzodiazepines (temazepam, triazolam) or Z-drugs in insomnia before any development investment is made
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.